MicroStockProfit.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
NexMed Inc. (NEXM) is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin's natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity.
Message Board Search for NEXM: http://www.boardcentral.com/boards/NEXM
In the report, the analyst notes:
"NEXM, a specialty CRO with a pipeline of products based on the NexACT® technology, recently announced that the Canadian Patent Office has issued a Notice of Allowance for NEXM's patent application entitled, 'Crystalline Salts of Dodecyl 2-(N,N-Dimethylamino)-Propionate.'
"NEXM recently announced that results from a pre-clinical study showed significant improvement in the delivery and half life of A6, a proprietary peptide treatment for ovarian cancer currently in phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model."
To read the entire report visit: www.microstockprofit.com/ads/NEXM
Childhood obesity not linked to adult skin cancer risk, study says